View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare...

OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, December 4th at 1:30 p.m. Eastern time. The fireside chat will be webcast live and available for replay in the Investors se...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 16, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTSH TILE SHOP HOLDINGS INC.
SEDG SOLAREDGE TECHNOLOGIES INC.
SATS ECHOSTAR CORPORATION CLASS A
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MCHX MARCHEX INC. CL B
KVHI KVH INDUSTRIES INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HASI
I3N HANNON ARMSTRONG SUSTAINABLE INFRASTRUCTURE CAPITAL INC.
GDOT CHART INDUSTRIES INC.
EXAS GREEN DOT CORPORATION CLASS A
CROX EXACT SCIENCES CORPORATION
CNC CROCS INC.
AGCO CENTENE CORPORATION
AVNW AGCO CORPORATION
ENPH AVIAT NETWORKS
HTLD ENPHASE ENERGY INC.
ZOM HEARTLAND EXPRESS INC.
DMLP ZOMEDICA PHARMACEUTICALS CORP
MAV DORCHESTER MINERALS L.P.
HLNE PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SNBR HAMILTON LANE INCORPORATED CLASS A
MHI SLEEP NUMBER CORPORATION
GNL PIONEER MUNICIPAL HIGH INCOME TRUST
BBDC GALEY & LORD INC.
CLDX BARINGS BDC INC.
ENX CELLDEX THERAPEUTICS INC.
ADV EATON VANCE NEW YORK MUNICIPAL BOND FUND
HPK ADVANTAGE SOLUTIONS INC (A)
MRVI HIGHPEAK ENERGY INC (A)
OPCH MARAVAI LIFESCIENCES HOLDINGS
MODV OPTION CARE HEALTH INC
DCOM MODIVCARE INC
UAN DIME COMMUNITY BANCSHARES
PFBX INC.
OSCR CVR PARTNERS LP
BGS PEOPLES FINANCIAL CORP. (MISSISSIPPI)
WBD OSCAR HEALTH
TCBX B&G FOODS
BIGZ INC.
RXO_w WARNER BROS. DISCOVERY INC.
VANI THIRD COAST BANCSHARES INC
KLG_w BLACKROCK INNOVATION AND GROWTH TST
DBD RXO INC
MIO VIVANI MEDICAL INC
WPC WK KELLOGG CO
EVM DIEBOLD NIXDORF INCORPORATED
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
W. P. CAREY AND CO. LLC
EATON VANCE INSD CALIF MUN BD FD

Opko Health Inc: 1 director

A director at Opko Health Inc bought 280,183 shares at 1.505USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 9, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: November 8, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

OPKO Health Reports Third Quarter 2024 Business Highlights and Financi...

OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: Completed sale of select assets of BioReference Health to Labcorp for $237.5 million. OPKO completed the sale of BioReference Health’s laboratory testing businesses focused on clinical diagn...

 PRESS RELEASE

OPKO Health to Report Third Quarter 2024 Financial Results on November...

OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Thursday, November 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on November 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages ...

 PRESS RELEASE

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COV...

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment work is based on ModeX proprietary MSTAR technology that incorporates multiple antibody binding sites into a single molecule WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces ...

 PRESS RELEASE

OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Ch...

OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. “Dr. Abbadessa’s deep ...

 PRESS RELEASE

OPKO Health Reports Second Quarter 2024 Business Highlights and Financ...

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second quarter and recent weeks include the following: Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid tumor cancers. MDX2001, a tetraspecific antibody, is designed to optimize T-cell function to stimulate tumor regression while mini...

 PRESS RELEASE

OPKO Health to Report Second Quarter 2024 Financial Results on August ...

OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024 MIAMI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on Wednesday, August 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on August 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participan...

 PRESS RELEASE

OPKO Health Announces $100 Million Share Repurchase Program

OPKO Health Announces $100 Million Share Repurchase Program MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock.   Under the repurchase program, OPKO may repurchase shares of its common stock from time to time through open market purchases, block trades, privately negotiated transactions, accelerated share repurchase transactions and/or pursuant to Rule 10b5-1 plans, in compliance with applicable securities laws and other legal requir...

 PRESS RELEASE

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purcha...

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA™, a once-weekly treatment currently marketed to treat pediatric growth hormone deficiency. “This transaction with HCRx allows OPKO to retain a significant portion of NGE...

 PRESS RELEASE

OPKO Health to Participate in the Jefferies Global Healthcare Conferen...

OPKO Health to Participate in the Jefferies Global Healthcare Conference MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Thursday, June 6th at 10:30 a.m. Eastern time. The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health’s website and...

 PRESS RELEASE

OPKO Health Reports First Quarter 2024 Business Highlights and Financi...

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights include the following: Entered into an agreement with Labcorp to sell select assets of BioReference Health. The transaction includes the sale of BioReference Health’s laboratory testing businesses focused on clinical diagnostics and women’s health, excludi...

 PRESS RELEASE

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2...

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register f...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: March 18, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch